A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Clinical trial NCT03093116 · RECRUITING

Trial details

NCT number: NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced Solid Tumors Metastatic Solid Tumors

Start date: 2017-03-07
Primary completion: 2028-02-29
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.